Emcure Pharmaceuticals Ltd. - Research Center
544210 EMCURE Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 18 | |
|---|---|---|---|---|---|
| Sales | 3,107.09 | 3,387.24 | 3,153.66 | 2,375.71 | 2,241.43 |
| Operating profit | 438.49 | 794.67 | 743.41 | 423.42 | 527.60 |
| Interest | 166.83 | 145.14 | 123.34 | 137.22 | 88.05 |
| Gross profit | 397.01 | 782.22 | 731.97 | 423.82 | 500.55 |
| EPS (Rs) | 8.85 | 24.71 | 23.25 | 9.69 | 13.42 |
Annual
results in details
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 18 | |
|---|---|---|---|---|---|
| Other income | 125.35 | 132.68 | 111.91 | 137.62 | 61.00 |
| Stock adjustment | 14.45 | -36.10 | -107.96 | 59.70 | 60.34 |
| Raw material | 938.87 | 1,072.09 | 1,047.32 | 559.85 | 370.95 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 649.18 | 603.95 | 550.96 | 545.35 | 484.13 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,066.10 | 952.64 | 919.94 | 787.39 | 798.41 |
| Provisions made | - | - | - | - | - |
| Depreciation | 178.52 | 165.79 | 156.24 | 154.97 | 119.97 |
| Taxation | 52.28 | 169.61 | 136.97 | 49.48 | 99.68 |
| Net profit / loss | 160.06 | 446.81 | 420.48 | 175.21 | 242.77 |
| Extra ordinary item | -6.15 | - | -18.29 | -44.16 | -38.14 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 180.85 | 180.85 | 180.85 | 180.85 | 180.85 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 14.11 | 23.46 | 23.57 | 17.82 | 23.54 |
| GPM (%) | 12.28 | 22.22 | 22.41 | 16.86 | 21.74 |
| NPM (%) | 4.95 | 12.69 | 12.88 | 6.97 | 10.54 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis